| SC 13G/A | 2024-02-09 | Capital International Investors | BeiGene, Ltd. | 103,421,157 | 7.6% | EDGAR |
| SC 13G/A | 2024-02-05 | OYLER JOHN | BeiGene, Ltd. | 71,464,808 | 5.2% | EDGAR |
| SC 13D/A | 2023-11-14 | BAKER BROS. ADVISORS LP | BeiGene, Ltd. | 138,222,377 | 10.2% | EDGAR |
| SC 13D/A | 2023-05-05 | BAKER BROS. ADVISORS LP | BeiGene, Ltd. | 152,522,377 | 11.2% | EDGAR |
| SC 13D/A | 2023-02-14 | HHLR ADVISORS, LTD. | BeiGene, Ltd. | 147,043,058 | 10.9% | EDGAR |
| SC 13G/A | 2023-02-13 | Capital International Investors | BeiGene, Ltd. | 110,215,170 | 8.2% | EDGAR |
| SC 13G/A | 2023-02-10 | Invesco Ltd. | BeiGene, Ltd. | 35,678,240 | 2.6% | EDGAR |
| SC 13G/A | 2023-02-10 | OYLER JOHN | BeiGene, Ltd. | 70,026,397 | 5.1% | EDGAR |
| SC 13D/A | 2022-08-16 | HHLR ADVISORS, LTD. | BeiGene, Ltd. | 147,035,258 | 10.9% | EDGAR |
| SC 13G/A | 2022-02-14 | OYLER JOHN | BeiGene, Ltd. | 69,558,605 | 5.1% | EDGAR |
| SC 13G/A | 2022-02-11 | Capital International Investors | BeiGene, Ltd. | 104,036,177 | 7.8% | EDGAR |
| SC 13G/A | 2022-02-11 | BeiGene, Ltd. | BeiGene, Ltd. | 69,558,605 | 5.1% | EDGAR |
| SC 13G | 2022-02-11 | Invesco Ltd. | BeiGene, Ltd. | 39,028,821 | 5.6% | EDGAR |
| SC 13G/A | 2022-02-09 | FMR LLC | BeiGene, Ltd. | 47,129,292 | 3.5% | EDGAR |
| SC 13D/A | 2021-09-29 | BeiGene, Ltd. | LEAP THERAPEUTICS, INC. | 12,153,074 | 13.2% | EDGAR |
| SC 13G/A | 2021-02-16 | Capital International Investors | BeiGene, Ltd. | 89,894,623 | 7.6% | EDGAR |
| SC 13G/A | 2021-02-11 | OYLER JOHN | BeiGene, Ltd. | 72,484,268 | 6.0% | EDGAR |
| SC 13G/A | 2021-02-08 | FMR LLC | BeiGene, Ltd. | 62,214,015 | 5.3% | EDGAR |
| SC 13D/A | 2020-12-04 | BAKER BROS. ADVISORS LP | BeiGene, Ltd. | 153,853,343 | 13.0% | EDGAR |
| SC 13D/A | 2020-07-17 | BAKER BROS. ADVISORS LP | BeiGene, Ltd. | 173,503,441 | 14.9% | EDGAR |